Recognizing the Disruptive Potential of Cancer Immunotherapy

This article from MDB Communications discusses ten cancer vaccine programs in mid- and late-stage development with important catalysts expected during the balance of 2013 and into 2014. The article also highlights how several of these newer products seem to work better and address the

Thinking of Spring – Tulips and Cancer Stem Cell Mania

With spring around the corner, it seemed an appropriate time to examine Wall Street’s latest tulip obsession, which relates to the potential of targeting cancer stem cells...

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Three Late-Stage Leukemia Company Previews for ASCO

Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.

Similarities Between Two Immunotherapies in Cancer

Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.

Ipilimumab Approval Highlights Immunotherapy Renaissance

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Investment Opportunities with Five Frontline Therapies for AML

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal b

Five Key Factors Weighing on Dendreon

Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of ca

Cancer Immunotherapy to Take Center Stage at ASCO

In early April 2010, we published a 150-page industry report titled “Cancer Vaccine Therapies: Failures and Future Opportunities,” which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discuss

Cyclin-dependent Cancer Confab Preview

For more than a century, the American Association of Cancer Research [AACR] has held its annual meeting and this weekend will kick off the 101st event in Washington, DC, which is being held April 17-21, 2010.  Many pharmaceutical and biotechnology companies will be presenting new data